Skip to main content
Premium Trial:

Request an Annual Quote

Steven Tregay

Premium
Cequent Pharmaceuticals said this week that Steven Tregay has been appointed to the company’s board of directors.
Tregay is a managing director of the Novartis Option Fund, a $200 million equity-investment fund operated by the Novartis Corporate Venture Funds. He joined Cequent’s board following an undisclosed investment in the company by the Novartis Option Fund (see related story, this issue).
 

Tregay has held several different roles with Novartis, and holds a PhD and MS in organic chemistry from Harvard University.

The Scan

Rise of BA.5

The New York Times reports that the Omicron subvariant BA.5 has become the dominant version of SARS-CoV-2 in the US.

UK Health Secretary Resigns

Sajid Javid, the UK health secretary, resigned along with Chancellor Rishi Sunak, saying they cannot work with Prime Minister Boris Johnson's government, CNN reports.

Clones From Freeze-Dried Cells

A team in Japan has cloned mice from freeze-dried skin cells, according to the Guardian.

Genome Research Papers on Craniosynostosis, Macaque Retrotransposition, More

In Genome Research this week: structural variants in craniosynostosis, LINE-1 activity in rhesus macaque brain, and more.